tracken
UroGen Pharma Ltd. Aktie News
Neutral
GlobeNewsWire
●
etwa 17 Stunden alt
Conference Call and Webcast Scheduled for Thursday, November 6th, 2025, at 10:00 AM ET Conference Call and Webcast Scheduled for Thursday, November 6th, 2025, at 10:00 AM ET
Neutral
GlobeNewsWire
●
4 Tage alt
PRINCETON, N.J., Oct. 27, 2025 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd.
Neutral
GlobeNewsWire
●
29 Tage alt
PRINCETON, N.J., Oct. 02, 2025 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd.
Neutral
GlobeNewsWire
●
etwa 2 Monate alt
PRINCETON, N.J., Sept. 08, 2025 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd.
Neutral
GlobeNewsWire
●
2 Monate alt
PRINCETON, N.J., Aug. 21, 2025 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd.
Positiv
Seeking Alpha
●
2 Monate alt
UroGen Pharma Ltd. recently secured FDA approval for Zusduri, its second commercial product, which is expected to significantly boost future revenues. Analysts remain bullish, with multiple Buy ratings and price targets between $31 and $47, reflecting optimism about the company's growth trajectory. Despite growing sales, UroGen continues to post net losses and will likely require a capital rais...
Neutral
Seeking Alpha
●
3 Monate alt
UroGen Pharma Ltd. (NASDAQ:URGN ) Q2 2025 Earnings Conference Call August 7, 2025 10:00 AM ET Company Participants Christopher Degnan - Chief Financial Officer David Lin - Chief Commercial Officer Elizabeth A.
Neutral
The Motley Fool
●
3 Monate alt
UroGen (URGN) Q2 Revenue Rises 11%
Kostenlos registrieren
aktien.guide ist das Tool zum einfachen Finden, Analysieren und Beobachten von Aktien. Lerne von erfolgreichen Investoren und triff fundierte Anlageentscheidungen. Wir machen Dich zum selbstbestimmten Investor.
